In light of the superior benefits of recombinant AAT-Fc over pAAT, the associated costs of pAAT vs. AAT-Fc, and the longer half-life of AAT-Fc, further development of AAT-Fc as a therapeutic tool in AAT-deficient and AAT-sufficient emphysema is warranted. The gene discussed is SERPINA1; the disease is pulmonary emphysema.